Drug Repositioning Strategies for Refueling the Pipeline

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• In Vivo Technologies
  • Real-Time Imaging in Animal Models
  • Zebra Fish Disease Models
  • In Vivo Multiplexing
• Ex Vivo Technologies
  • Kinetic Markers
  • Metabolomics
    • Metabolon
    • Gene Logic
• In Vitro Cell-Based Technologies
  • Bionaut Pharmaceuticals
  • CombinatoRx
  • Gene Logic
• In Silico Technologies
  • Arachnova
  • Inpharmatica
  • Off-label.com
  • Sosei
  • Gene Logic
• Repositioning Within a Therapeutic Area
  • Dynogen
  • Jenken Biosciences
  • Vicus Therapeutics
  • BrainCells
• Strategies in Drug Repositioning
  • Technology Strategies
  • Intellectual Property Strategies
  • Business Models
• Outlook for Drug Repositioning

Tables

• 1. Select Technologies for Drug Repositioning
• 2. Select Companies with Drug Repositioning Technologies or Programs
• 3. Select Collaborations in Drug Repositioning

Figures

• 1. Number of FDA-Approved New Molecular Entities (1997-2006) and Total Global R&D Spending, PhRMA Members (1997-2005)
• 2. In Vivo and Ex Vivo Technologies for Drug Repositioning
• 3. In Vitro, Cell-Based Assays for Drug Repositioning
• 4. In Silico Technologies for Drug Repositioning